Integrin antagonists as therapeutics for inflammatory diseases

Bibliogrpahy

• HYNES RO: Integrins: a family of cell surface receptors. Cell (1987) 48:549-554.
   PubMed Web of Science ®Google Scholar
• HEMLER ME, HUANG C, TAKADA Y, SCHWARZ L, STROMINGER JL, CLABBY ML: Characterization of the cell surface heterodimer VLA-4 and related peptides. J. Biol. Chem. (1987) 262:11478-11485.
   PubMed Web of Science ®Google Scholar
• HYNES RO: Integrins: bidirectional, allosteric signaling machines. Cell (2002) 110:673-687.
   PubMed Web of Science ®Google Scholar
• RUOSLAHTI E: Integrins. J. Clin. Invest. (1991) 87:1-5.
   PubMed Web of Science ®Google Scholar
• SPRINGER TA: Adhesion receptors of the immune system. Nature (1990) 346:425-434.
   PubMed Web of Science ®Google Scholar
• XIONG JP, STEHLE T, DIEFENBACH B et al.: Crystal structure of the extracellular segment of integrin αVβ3. Science (2001) 294:339-345.
   PubMed Web of Science ®Google Scholar
• WHITTAKER CA, HYNES RO: Distribution and evolution of von Willebrand/integrin A domains: widely dispersed domains with roles in cell adhesion and elsewhere. Mol. Biol. Cell (2002) 13:3369-3387.
   Google Scholar
• SCHWARTZ MA, SCHALLER MD, GINSBERG MH: Integrins: emerging paradigms of signal transduction. Ann. Rev. Cell Dev. Biol. (1995) 11:549-599.
   Google Scholar
• DUSTIN ML, SPRINGER TA: T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. Nature (1989) 341:619-624.
   PubMed Web of Science ®Google Scholar
• CARMAN CV, SPRINGER TA: Integrin avidity regulation: are changes in affinity and conformation underemphasized? Curr. Opin. Cell Biol. (2003) 15:547-556.
   Web of Science ®Google Scholar
• BAZZONI G, HEMLER ME: Are changes in integrin affinity and conformation overemphasized? Trends Biochem. Sci. (1998) 23:30-34.
   PubMed Web of Science ®Google Scholar
• LAUDANNA C, KIM JY, CONSTANTIN G, BUTCHER E: Rapid leukocyte integrin activation by chemokines. Immunol. Rev. (2002) 186:37-46.
   Google Scholar
• XIONG JP, STEHLE T, ZHANG R et al.: Crystal structure of the extracellular segment of integrin αVβ3 in complex with an Arg-Gly-Asp ligand. Science (2002) 296:151-155.
   PubMed Web of Science ®Google Scholar
• SHIMAOKA M, SALAS A, YANG W, WEITZ-SCHMIDT G, SPRINGER TA: Small molecule integrin antagonists that bind to the β2 subunit I-like domain and activate signals in one direction and block them in the other. Immunity (2003) 19:391-402.
   PubMed Web of Science ®Google Scholar
• ARNAOUT MA, MAHALINGAM B, XIONG JP: Integrin structure, allostery, and bidirectional signaling. Ann. Rev. Cell Dev. Biol. (2005) 21:381-410.
   Google Scholar
• FRELINGER AL III, COHEN I, PLOW EF et al.: Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers. J. Biol. Chem. (1990) 265:6346-6352.
   PubMed Web of Science ®Google Scholar
• FRELINGER AL III, DU X, PLOW EF, GINSBERG MH: Monoclonal antibodies to ligand-occupied conformers of integrin αIIbβ3 (glycoprotein IIb-IIIa) alter receptor affinity, specificity, and function. J. Biol. Chem. (1991) 266:17106-17111.
   PubMed Web of Science ®Google Scholar
• EMSLEY J, KNIGHT CG, FARNDALE RW, BARNES MJ, LIDDINGTON RC: Structural basis of collagen recognition by integrin α2β1. Cell (2000) 101:47-56.
   PubMed Web of Science ®Google Scholar
• SHIMAOKA M, XIAO T, LIU JH et al.: Structures of the α L I domain and its complex with ICAM-1 reveal a shape-shifting pathway for integrin regulation. Cell (2003) 112:99-111.
   PubMed Web of Science ®Google Scholar
• XIAO T, TAKAGI J, COLLER BS, WANG JH, SPRINGER TA: Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. Nature (2004) 432:59-67.
   PubMed Web of Science ®Google Scholar
• ELICES MJ, OSBORN L, TAKADA Y et al.: VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4/fibronectin binding site. Cell (1990) 60:577-584.
   PubMed Web of Science ®Google Scholar
• KERN A, EBLE J, GOLBIK R, KUHN K: Interaction of type IV collagen with the isolated integrins α1β1 and α2β1. Eur. J. Biochem. (1993) 215:151-159.
   Google Scholar
• CALDERWOOD DA, TUCKWELL DS, EBLE J, KUHN K, HUMPHRIES MJ: The integrin α1 A-domain is a ligand binding site for collagens and laminin. J. Biol. Chem. (1997) 272:12311-12317.
   PubMed Web of Science ®Google Scholar
• MIYAUCHI A, ALVAREZ J, GREENFIELD EM et al.: Recognition of osteopontin and related peptides by an αvβ3 integrin stimulates immediate cell signals in osteoclasts. J. Biol. Chem. (1991) 266:20369-20374.
   PubMed Web of Science ®Google Scholar
• WICKHAM TJ, MATHIAS P, CHERESH DA, NEMEROW GR: Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachment. Cell (1993) 73:309-319.
   PubMed Web of Science ®Google Scholar
• ENNIS E, ISBERG RR, SHIMIZU Y: Very late antigen 4-dependent adhesion and costimulation of resting human T cells by the bacterial β1 integrin ligand invasin. J. Exp. Med. (1993) 177:207-212.
   Google Scholar
• ETO K, PUZON-McLAUGHLIN W, SHEPPARD D, SEHARA-FUJISAWA A, ZHANG XP, TAKADA Y: RGD-independent binding of integrin α9β1 to the ADAM-12 and -15 disintegrin domains mediates cell–cell interaction. J. Biol. Chem. (2000) 275:34922-34930.
   PubMed Web of Science ®Google Scholar
• STEFANIDAKIS M, BJORKLUND M, IHANUS E, GAHMBERG CG, KOIVUNEN E: Identification of a negatively charged peptide motif within the catalytic domain of progelatinases that mediates binding to leukocyte β2 integrins. J. Biol. Chem. (2003) 278:34674-34684.
   PubMed Web of Science ®Google Scholar
• SCARBOROUGH RM, ROSE JW, NAUGHTON MA et al.: Characterization of the integrin specificities of disintegrins isolated from American pit viper venoms. J. Biol. Chem. (1993) 268:1058-1065.
   PubMed Web of Science ®Google Scholar
• SPRINGER TA: Folding of the N-terminal, ligand-binding region of integrin α-subunits into a β-propeller domain. Proc. Natl. Acad. Sci. USA (1997) 94:65-72.
   PubMed Web of Science ®Google Scholar
• RICH Rl, DEIVANAYAGAM CC, OWENS RT et al.: Trench-shaped binding sites promote multiple classes of interactions between collagen and the adherence receptors, α1β1 integrin and Staphylococcus aureus cna MSCRAMM. J. Biol. Chem. (1999) 274:24906-24913.
   PubMed Web of Science ®Google Scholar
• PYTELA R: Amino acid sequence of the murine Mac-1 α chain reveals homology with the integrin family and an additional domain related to von Willebrand factor. EMBO J. (1988) 7:1371-1378.
   PubMed Web of Science ®Google Scholar
• MICHISHITA M, VIDEM V, ARNAOUT MA: A novel divalent cation-binding site in the A domain of the β2 integrin CR3 (Cd11b/CD18) is essential for ligand binding. Cell (1993) 72:857-867.
   PubMed Web of Science ®Google Scholar
• RANDI AM, HOGG N: I domain of β2 integrin lymphocyte function-associated antigen-1 contains a binding site for ligand intercellular adhesion molecule-1. J. Biol. Chem. (1994) 269:12395-12398.
   PubMed Web of Science ®Google Scholar
• LEITINGER B, HOGG N: Effects of I domain deletion on the function of the β2 integrin lymphocyte function-associated antigen-1. Mol. Biol. Cell (2000) 11:677-690.
   Google Scholar
• YALAMANCHILI P, LU C, OXVIG C, SPRINGER TA: Folding and function of I domain-deleted Mac-1 and lymphocyte function- associated antigen-1. J. Biol. Chem. (2000) 275:21877-21882.
   PubMed Web of Science ®Google Scholar
• SHIMAOKA M, SPRINGER TA: Therapeutic antagonists and conformational regulation of integrin function. Nat. Rev. Drug Discov. (2003) 2:703-716.
   Google Scholar
• YOU TJ, MAXWELL DS, KOGAN TP et al.: A 3D structure model of integrin α4β1 complex: I. Construction of a homology model of β1 and ligand binding analysis. Biophys. J. (2002) 82:447-457.
   PubMed Web of Science ®Google Scholar
• KALLEN J, WELZENBACH K, RAMAGE P et al.: Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J. Mol. Biol. (1999) 292:1-9.
   Google Scholar
• WEITZ-SCHMIDT G, WELZENBACH K, BRINKMANN V et al.: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat. Med. (2001) 7:687-692.
   Google Scholar
• LU C, SHIMAOKA M, FERZLY M, OXVIG C, TAKAGI J, SPRINGER TA: An isolated, surface-expressed I domain of the integrin αLβ2 is sufficient for strong adhesive function when locked in the open conformation with a disulfide bond. Proc. Natl. Acad. Sci. USA (2001) 98:2387-2392.
   PubMed Web of Science ®Google Scholar
• LU C, SHIMAOKA M, ZANG Q, TAKAGI J, SPRINGER TA: Locking in alternate conformations of the integrin αLβ2 I domain with disulfide bonds reveals functional relationships among integrin domains. Proc. Natl. Acad. Sci. USA (2001) 98:2393-2398.
   PubMed Web of Science ®Google Scholar
• KOIVUNEN E, RANTA TM, ANNILA A et al.: Inhibition of β2 integrin-mediated leukocyte cell adhesion by leucine- leucine-glycine motif-containing peptides. J. Cell Biol. (2001) 153:905-916.
   PubMed Web of Science ®Google Scholar
• BOCHNER BS, LUSCINSKAS FW, GIMBRONE MA et al.: Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. J. Exp. Med. (1991) 173:1553-1557.
   Google Scholar
• KUBES P, NIU X-F, SMITH CW, KEHRLI ME, REINHARDT PH, WOODMAN R: A novel β1 -dependent adhesion pathway on neutrophils: a mechanism invoked by dihydrocytochalasin B or endothelial transmigration. FASEB J. (1995) 9:1103-1111.
   PubMed Web of Science ®Google Scholar
• ISSEKUTZ TB, MIYASAKA M, ISSEKUTZ AC: Rat blood neutrophils express very late antigen 4 and it mediates migration to arthritic joint and dermal inflammation. J. Exp. Med. (1996) 183:2175-2184.
   Google Scholar
• ERLE DJ, BRISKIN MJ, BUTCHER EC, GARCIA-PARDO A, LAZAROVITS AI, TIDSWELL M: Expression and function of the MAdCAM-1 receptor, integrin α4β7, on human leukocytes. J. Immunol. (1994) 153:517-528.
   Google Scholar
• RUEGG C, POSTIGO AA, SIKORSKI EE, BUTCHER EC, PYTELA R, ERLE DJ: Role of integrin α4β7/α4βP in lymphocyte adherence to fibronectin and VCAM-1 and in homotypic cell clustering. J. Cell Biol. (1992) 117:179-189.
   PubMed Web of Science ®Google Scholar
• WAYNER EA, GARCIA-PARDO A, HUMPHRIES MJ, McDONALD JA, CARTER WG: Identification and characterization of the T lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin. J. Cell Biol. (1989) 109:1321-1330.
   PubMed Web of Science ®Google Scholar
• BERLIN C, BERG EL, BRISKIN MJ et al.: α4β7 integrin mediates lymphocyte binding to the mucosal vascular addressin madcam-1. Cell (1993) 74:185-195.
   PubMed Web of Science ®Google Scholar
• BRISKIN M, WINSOR-HINES D, SHYJAN A et al.: Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am. J. Pathol. (1997) 151:97-110.
   PubMed Web of Science ®Google Scholar
• NEWHAM P, CRAIG SE, SEDDON GN et al.: α4 integrin binding interfaces on VCAM-1 and MAdCAM-1. Integrin binding footprints identify accessory binding sites that play a role in integrin specificity. J. Biol. Chem. (1997) 272:19429-19440.
   PubMed Web of Science ®Google Scholar
• SPRING FA, PARSONS SF, ORTLEPP S et al.: Intercellular adhesion molecule-4 binds α4β1 and αV-family integrins through novel integrin-binding mechanisms. Blood (2001) 98:458-466.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM SA, RODRIGUEZ JM, ARRATE MP, TRAN TM, BROCK TA: JAM2 interacts with α4β1. Facilitation by JAM3. J. Biol. Chem. (2002) 277:27589-27592.
   PubMed Web of Science ®Google Scholar
• ALTEVOGT P, HUBBE M, RUPPERT M et al.: The α4 integrin chain is a ligand for α4β7 and α4β1. J. Exp. Med. (1995) 182:345-355.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ, COLOMBEL JF, ENNS R et al.: Natalizumab induction and maintenance therapy for Crohn’s disease. N. Engl. J. Med. (2005) 353:1912-1925.
   PubMed Web of Science ®Google Scholar
• MILLER DH, KHAN OA, SHEREMATA WA et al.: A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. (2003) 348:15-23.
   PubMed Web of Science ®Google Scholar
• POLMAN CH, O’CONNOR PW, HAVRDOVA E et al.: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. (2006) 354:899-910.
   PubMed Web of Science ®Google Scholar
• ABRAHAM WM, SIELCZAK MW, AHMED A et al.: α4-integrins mediate antigen-induced late bronchial responses and prolonged airway hyperresponsiveness in sheep. J. Clin. Invest. (1994) 93:776-787.
   PubMed Web of Science ®Google Scholar
• HENDERSON WR, CHI EY, ALBERT RK et al.: Blockade of CD49d (α4 integrin) on intrapulmonary but not circulating leukocytes inhibits airway inflammation and hyperresponsiveness in a mouse model of asthma. J. Clin. Invest. (1997) 100:3083-3092.
   PubMed Web of Science ®Google Scholar
• HOJO M, MAGHNI K, ISSEKUTZ TB, MARTIN JQ: Involvement of α4 integrins in allergic airway responses and mast cell degranulation in vivo. Am. J. Respir. Crit. Care Med. (1998) 158:1127-1133.
   Google Scholar
• METZGER WJ: Therapeutic approaches to asthma based on VLA-4 integrin and its counter receptors. Springer Semin. Immunopathol. (1995) 16:467-478.
   PubMed Web of Science ®Google Scholar
• PRETOLANI M, RUFFIE C, LAPA E SILVA JR, JOSEPH D, LOBB RR, VARGAFTIG BB: Antibody to very late activation antigen 4 prevents antigen-induced bronchial hyperreactivity and cellular infiltration in the guinea pig airways. J. Exp. Med. (1994) 180:795-805.
   Google Scholar
• FEAGAN BG, GREENBERG GR, WILD G et al.: Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin. N. Engl. J. Med. (2005) 352:2499-2507.
   PubMed Web of Science ®Google Scholar
• HESTERBERG PE, WINSOR-HINES D, BRISKIN MJ et al.: Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin α4β7. Gastroenterology (1996) 111:1373-1380.
   PubMed Web of Science ®Google Scholar
• KATO S, HOKARI R, MATSUZAKI K et al.: Amelioration of murine experimental colitis by inhibition of mucosal addressin cell adhesion molecule-1. J. Pharmacol. Exp. Ther. (2000) 295:183-189.
   Google Scholar
• PICARELLA D, HURLBUT P, ROTTMAN J, SHI X, BUTCHER E, RINGLER DJ: Monoclonal antibodies specific for β7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RDhigh CD4+ T cells. J. Immunol. (1997) 158:2099-2106.
   PubMed Web of Science ®Google Scholar
• PODOLSKY DK, LOBB R, KING N et al.: Attenuation of colitis in the cotton-top tamarin by anti-α4 integrin monoclonal antibody. J. Clin. Invest. (1993) 92:372-380.
   PubMed Web of Science ®Google Scholar
• SEIFFGE D: Protective effects of monoclonal antibody to VLA-4 on leukocyte adhesion and course of disease in adjuvant arthritis in rats. J. Rheumatol. (1996) 23:2086-2091.
   Google Scholar
• WAHL SM, ALLEN JB, HINES KL et al.: Synthetic fibronectin peptides suppress arthritis in rats by interrupting leukocyte adhesion and recruitment. J. Clin. Invest. (1994) 94:655-662.
   PubMed Web of Science ®Google Scholar
• ABRAHAM WM, GILL A, AHMED A et al.: A small-molecule, tight-binding inhibitor of the integrin α4β1 blocks antigen-induced airway responses and inflammation in experimental asthma in sheep. Am. J. Respir. Crit. Care Med. (2000) 162:603-611.
   Google Scholar
• KOO GC, SHAH K, DING GJ et al.: A small molecule very late antigen-4 antagonist can inhibit ovalbumin-induced lung inflammation. Am. J. Respir. Crit. Care Med. (2003) 167:1400-1409.
   Google Scholar
• BURKLY LC, JAKUBOWSKI A, NEWMAN BM, ROSA MD, CHI-ROSSO G, LOBB RR: Signaling by vascular cell adhesion molecule-1 (VCAM-1) through VLA-4 promotes CD3-dependent T cell proliferation. Eur. J. Immunol. (1991) 21:2871-2875.
   Google Scholar
• SHIMIZU Y, SEVENTER GAV, HORGAN KJ, SHAW S: Costimulation of proliferative responses of resting CD4+ T cells by the interaction of VLA-4 and VLA-5 with fibronectin or VLA-6 with laminin. J. Immunol. (1990) 145:59-67.
   Google Scholar
• DIAMANT Z, KUPERUS J, BAAN R et al.: Effect of a very late antigen-4 receptor antagonist on allergen-induced airway responses and inflammation in asthma. Clin. Exp. Allergy (2005) 35:1080-1087.
   Google Scholar
• NORRIS V, CHOONG L, TRAN D et al.: Effect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma. J. Allergy Clin. Immunol. (2005) 116:761-767.
   Google Scholar
• HIJAZI Y, WELKER H, DORR AE et al.: Pharmacokinetics, safety, and tolerability of R411, a dual α4β1–α4β7 integrin antagonist after oral administration at single and multiple once-daily ascending doses in healthy volunteers. J. Clin. Pharmacol. (2004) 44:1368-1378.
   Google Scholar
• LAFFON A, GARCIA-VICUNA R, HUMBRIA A, POSTIGO AA, CORBI AL: Upregulated expression and function of VLA-4 fibronectin receptors on human activated T cells in rheumatoid arthritis. J. Clin. Invest. (1991) 88:546-552.
   PubMed Web of Science ®Google Scholar
• MORALES-DUCRET J, WAYNER E, ELICES MJ, ALVARO-GRACIA JM, ZVAIFLER NJ, FIRESTEIN GS: α4/β1 integrin (VLA-4) ligands in arthritis. Vascular cell adhesion molecule-1 expression in synovium and on fibroblast-like synoviocytes. J. Immunol. (1992) 149:1424-1431.
   Google Scholar
• MULLER-LADNER U, ELICES MJ, KRIEGSMANN JB et al.: Alternatively spliced CS-1 fibronectin isoform and its receptor VLA-4 in rheumatoid arthritis synovium. J. Rheumatol. (1997) 24:1873-1880.
   Google Scholar
• WELLICOME SM, KAPAHI P, MASON JC, LEBRANCHU Y, YARWOOD H, HASKARD DO: Detection of a circulating form of vascular cell adhesion molecule-1: raised levels in rheumatoid arthritis and systemic lupus erythematosus. Clin. Exp. Immunol. (1993) 92:412.
   Google Scholar
• KITANI A, NAKASHIMA N, IZUMIHARA T et al.: Soluble VCAM-1 induces chemotaxis of jurkat and synovial fluid cells bearing high affinity very late antigen-4. J. Immunol. (1998) 161:4931-4938.
   Google Scholar
• KOCH AE, HALLORAN MM, HASKELL CJ, SHAH MR, POLVERINI PJ: Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature (1995) 376:517-519.
   PubMed Web of Science ®Google Scholar
• MITTELBRUNN M, MOLINA A, ESCRIBESE MM et al.: VLA-4 integrin concentrates at the peripheral supramolecular activation complex of the immune synapse and drives T helper 1 responses. Proc. Natl. Acad. Sci. USA (2004) 101:11058-11063.
   PubMed Web of Science ®Google Scholar
• BEDNARCZYK JL, TEAGUE TK, WYGANT JN, DAVIS LS, LIPSKY PE, McINTYRE BW: Regulation of T cell proliferation by anti-CD49d and anti-CD29 monoclonal antibodies. J. Leuk. Biol. (1992) 52:456-462.
   PubMed Web of Science ®Google Scholar
• NOJIMA Y, HUMPHRIES MJ, MOULD AP et al.: VLA-4 mediates CD3-dependent CD4+ T cell activation via the CS1 alternatively spliced domain of fibronectin. J. Exp. Med. (1990) 172:1185-1192.
   Google Scholar
• DAVIS LS, OPPENHEIMER MARKS N, BEDNARCZYK JL, McINTYRE BW, LIPSKY PE: Fibronectin promotes proliferation of naive and memory T cells by signaling through both the VLA-4 and VLA-5 integrin molecules. J. Immunol. (1990) 145:785-793.
   Google Scholar
• COITO AJ, KOROM S, HANCOCK WW, KUPIEC-WEGLINSKI JW: Blockade of α4β1-integrin–fibronectin adhesive interactions prevents chronic allograft rejection in sensitized recipients. Transplant. Proc. (1998) 30:939-940.
   Web of Science ®Google Scholar
• SUZUKI J, ISOBE M, IZAWA A et al.: Differential Th1 and Th2 cell regulation of murine cardiac allograft acceptance by blocking cell adhesion of ICAM-1/LFA-1 and VCAM-1/VLA-4. Transpl. Immunol. (1999) 7:65-72.
   Google Scholar
• KLEINSCHMIDT-DEMASTERS BK, TYLER KL: Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon β1a for multiple sclerosis. N. Engl. J. Med. (2005) 353:369-374.
   PubMed Web of Science ®Google Scholar
• LANGER-GOULD A, ATLAS SW, GREEN AJ, BOLLEN AW, PELLETIER D: Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N. Engl. J. Med. (2005) 353:375-381.
   PubMed Web of Science ®Google Scholar
• VAN ASSCHE G, VAN RANST M, SCIOT R et al.: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N. Engl. J. Med. (2005) 353:362-368.
   PubMed Web of Science ®Google Scholar
• PADGETT BL, WALKER DL: Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. J. Infect. Dis. (1973) 127:467-470.
   Google Scholar
• YOUSRY TA, MAJOR EO, RYSCHKEWITSCH C et al.: Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. (2006) 354:924-933.
   PubMed Web of Science ®Google Scholar
• GURTNER GC, DAVIS V, LI H, McCOY MJ, SHARP A, CYBULSKY MI: Targeted disruption of the murine VCAM-1 gene: essential role of VCAM-1 in chorioallantoic fusion and placentation. Genes Dev. (1995) 9:1-14.
   PubMed Web of Science ®Google Scholar
• KWEE L, BALDWIN S, STEWART CS, BUCK CA, LABOW MA: Defective development of embryonic and extraembryonic circulatory systems in vascular cell adhesion molecule (VCAM-1) deficient mice. Development (1995) 121:489-503.
   PubMed Web of Science ®Google Scholar
• YANG JT, RAYBURN H, HYNES RO: Cell adhesion events by α4 integrins are essential in placental and cardiac development. Development (1995) 121:549-560.
   PubMed Web of Science ®Google Scholar
• SPENCE S, VETTER C, HAGMANN WK et al.: Effects of VLA-4 antagonists in rat whole embryo culture. Teratology (2002) 65:26-37.
   PubMedGoogle Scholar
• CROFTS F, PINO M, DELISE B et al.: Different embryo-fetal toxicity effects for three VLA-4 antagonists. Birth Defects Res. B Dev. Reprod. Toxicol. (2004) 71:55-68.
   Google Scholar
• CROFTS F, ROHATAGI S, PINO M et al.: Critical period for a teratogenic VLA-4 antagonist: Developmental effects and comparison of embryo drug concentrations of teratogenic and non-teratogenic VLA-4 antagonists. Birth Defects Res. B Dev. Reprod. Toxicol. (2004) 71:69-79.
   Google Scholar
• MILLER LJ, SCHWARTING R, SPRINGER TA: Regulated expression of the Mac-1, LFA-1, p150,95 glycoprotein family during leukocyte differentiation. J. Immunol. (1986) 137:2891-2900.
   Google Scholar
• SHORTMAN K, LIU YJ: Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. (2002) 2:151-161.
   Google Scholar
• VAN DER VIEREN M, TRONG Hl, WOOD Cl et al.: A novel leukointegrin, αdβ2, binds preferentially to ICAM-3. Immunity (1995) 3:683-690.
   PubMed Web of Science ®Google Scholar
• GRAYSON MH, VAN DER VIEREN M, STERBINSKY SA et al.: αdβ2 integrin is expressed on human eosinophils and functions as an alternative ligand for vascular cell adhesion molecule 1 (VCAM-1). J. Exp. Med. (1998) 188:2187-2191.
   Google Scholar
• DUSTIN Ml, SPRINGER TA: Lymphocyte function-associated antigen-1 (LFA-1) interaction with intercellular adhesion molecule-1 (ICAM-1) is one of at least three mechanisms for lymphocyte adhesion to cultured endothelial cells. J. Cell Biol. (1988) 107:321-331.
   PubMed Web of Science ®Google Scholar
• DIAMOND MS, STAUNTON DE, DE FOUGEROLLES AR et al.: ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18). J. Cell Biol. (1990) 111:3129-3139.
   PubMed Web of Science ®Google Scholar
• DIAMOND MS, GARCIA-AGUILAR J, BICKFORD JK, CORBI AL, SPRINGER TA: The I domain is a major recognition site on the leukocyte integrin Mac-1 (CD11b/CD18) for four distinct adhesion ligands. J. Cell Biol. (1993) 120:1031-1043.
   PubMed Web of Science ®Google Scholar
• STAUNTON DE, DUSTIN ML, SPRINGER TA: Functional cloning of ICAM-2, a cell adhesion ligand for LFA-1 homologous to ICAM-1. Nature (1989) 339:61-64.
   PubMed Web of Science ®Google Scholar
• XIE J, LI R, KOTOVUORI P, VERMOT-DESROCHES C et al.: Intercellular adhesion molecule-2 (CD102) binds to the leukocyte integrin CD11b/CD18 through the A domain. J. Immunol. (1995) 155:3619-3628.
   Google Scholar
• SHANG XZ, ISSEKUTZ AC: Contribution of CD11a/CD18, CD11b/CD18, ICAM-1 (CD54) and -2 (CD102) to human monocyte migration through endothelium and connective tissue fibroblast barriers. Eur. J. Immunol. (1998) 28:1970-1979.
   Google Scholar
• ISSEKUTZ AC, ROWTER D, SPRINGER TA: Role of ICAM-1 and ICAM-2 and alternate CD11/CD18 ligands in neutrophil transendothelial migration. J. Leukoc. Biol. (1999) 65:117-126.
   Google Scholar
• DE FOUGEROLLES AR, SPRINGER TA: Intercellular adhesion molecule 3, a third adhesion counter-receptor for lymphocyte function associated molecule 1 on resting lymphocytes. J. Exp. Med. (1992) 175:185-190.
   Google Scholar
• TIAN L, KILGANNON P, YOSHIHARA Y et al.: Binding of T lymphocytes to hippocampal neurons through ICAM-5 (telencephalin) and characterization of its interaction with the leukocyte integrin CD11a/CD18. Eur. J. Immunol. (2000) 30:810-818.
   Google Scholar
• YANG J, LINDSBERG PJ, HUKKANEN V, SELJELID R, GAHMBERG CG, MERI S: Differential expression of cytokines (IL-2, IFN-γ, IL-10) and adhesion molecules (VCAM-1, LFA-1, CD44) between spleen and lymph nodes associates with remission in chronic relapsing experimental autoimmune encephalomyelitis. Scand. J. Immunol. (2002) 56:286-293.
   Google Scholar
• MICKLEM KJ, SIM RB: Isolation of complement-fragment-iC3b-binding proteins by affinity chromatography. The identification of p150,95 as an iC3b-binding protein. Biochem. J. (1985) 231:233-236.
   Google Scholar
• LOIKE JD, SODEIK B, CAO L et al.: CD11c/CD18 on neutrophils recognizes a domain at the N terminus of the A α chain of fibrinogen. Proc. Natl. Acad. Sci. USA (1991) 88:1044-1048.
   PubMed Web of Science ®Google Scholar
• OSTERMANN G, WEBER KS, ZERNECKE A, SCHRODER A, WEBER C: JAM-1 is a ligand of the β2 integrin LFA-1 involved in transendothelial migration of leukocytes. Nat. Immunol. (2002) 3:151-158.
   Google Scholar
• SANTOSO S, SACHS UJ, KROLL H et al.: The junctional adhesion molecule 3 (JAM-3) on human platelets is a counterreceptor for the leukocyte integrin Mac-1. J. Exp. Med. (2002) 196:679-691.
   Google Scholar
• ARNAOUT MA, PITT J, COHEN HJ, MELAMED J, ROSEN FS, COLTEN HR: Deficiency of a granulocyte-membrane glycoprotein (gp150) in a boy with recurrent bacterial infections. N. Engl. J. Med. (1982) 306:693-699.
   PubMed Web of Science ®Google Scholar
• ANDERSON DC, SCHALMSTEIG FC, FINEGOLD MJ et al.: The severe and moderate phenotypes of heritable Mac-1, LFA-1 deficiency: their quantitative definition and relation to leukocyte dysfunction and clinical features. J. Infect. Dis. (1985) 152:668-689.
   Google Scholar
• ANDERSON DC, SPRINGER TA: Leukocyte adhesion deficiency: an inherited defect in the Mac-1, LFA-1, and p150-95 glycoproteins. Ann. Rev. Med. (1987) 38:175-183.
   Web of Science ®Google Scholar
• SPRINGER TA, THOMPSON WS, MILLER LJ, SCHMALSTIEG FC, ANDERSON DC: Inherited deficiency of the Mac-1, LFA-1, p150,95 glycoprotein family and its molecular basis. J. Exp. Med. (1984) 160:1901-1918.
   Google Scholar
• CROWLEY CA, CURNUTTE JT, ROSIN RE et al.: An inherited abnormality of neutrophil adhesion. Its genetic transmission and its association with a missing protein. N. Engl. J. Med. (1980) 302:1163-1168.
   PubMed Web of Science ®Google Scholar
• BOWEN TJ, OCHS HD, ALTMAN LC et al.: Severe recurrent bacterial infections associated with defective adherence and chemotaxis in two patients with neutrophils deficient in a cell-associated glycoprotein. J. Pediatr. (1982) 101:932-940.
   Google Scholar
• WACHOLTZ MC, PATEL SS, LIPSKY PE: Leukocyte function-associated antigen 1 is an activation molecule for human T cells. J. Exp. Med. (1989) 170:431-448.
   Google Scholar
• HOURMANT M, BEDROSSIAN J, DURAND D et al.: A randomized multicenter trial comparing leukocyte function-associated antigen-1 monoclonal antibody with rabbit antithymocyte globulin as induction treatment in first kidney transplantations. Transplantation (1996) 62:1565-1570.
   PubMed Web of Science ®Google Scholar
• CHIN YH, FALANGA V, STREILEIN JW, SACKSTEIN R: Lymphocyte recognition of psoriatic endothelium: evidence for a tissue-specific receptor/ligand interaction. J. Invest. Dermatol. (1989) 93:82S-87S.
   Google Scholar
• SACKSTEIN R, FALANGA V, STREILEIN JW, CHIN YH: Lymphocyte adhesion to psoriatic dermal endothelium is mediated by a tissue-specific receptor/ligand interaction. J. Invest. Dermatol. (1988) 91:423-428.
   Google Scholar
• McGREGOR JM, BARKER JN, ROSS EL, MacDONALD DM: Epidermal dendritic cells in psoriasis possess a phenotype associated with antigen presentation: in situ expression of β2-integrins. J. Am. Acad. Dermatol. (1992) 27:383-388.
   Google Scholar
• HORROCKS C, DUNCAN JI, OLIVER AM, THOMSON AW: Adhesion molecule expression in psoriatic skin lesions and the influence of cyclosporin A. Clin. Exp. Immunol. (1991) 84:157-162.
   Google Scholar
• GRIFFITHS CE, VOORHEES JJ, NICKOLOFF BJ: Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant γ interferon and tumor necrosis factor. J. Am. Acad. Dermatol. (1989) 20:617-629.
   Google Scholar
• ZEIGLER M, CHI Y, TUMAS DB, BODARY S, TANG H, VARANI J: Anti-CD11a ameliorates disease in the human psoriatic skin-SCID mouse transplant model: comparison of antibody to CD11a with cyclosporin A and clobetasol propionate. Lab. Invest. (2001) 81:1253-1261.
   Google Scholar
• LEBWOHL M, TYRING SK, HAMILTON TK et al.: A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N. Engl. J. Med. (2003) 349:2004-2013.
   PubMed Web of Science ®Google Scholar
• LINDSLEY HB, SMITH DD, COHICK CB, KOCH AE, DAVIS LS: Proinflammatory cytokines enhance human synoviocyte expression of functional intercellular adhesion molecule-1 (ICAM-1). Clin. Immunol. Immunopathol. (1993) 68:311-320.
   PubMedGoogle Scholar
• BULLARD DC, HURLEY LA, LORENZO I, SLY LM, BEAUDET AL, STAITE ND: Reduced susceptibility to collagen-induced arthritis in mice deficient in intercellular adhesion molecule-1. J. Immunol. (1996) 157:3153-3158.
   Google Scholar
• KAVANAUGH AF, DAVIS LS, NICHOLS LA et al.: Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum. (1994) 37:992-999.
   PubMed Web of Science ®Google Scholar
• KAVANAUGH AF, SCHULZE-KOOPS H, DAVIS LS, LIPSKY PE: Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody. Arthritis Rheum. (1997) 40:849-853.
   PubMed Web of Science ®Google Scholar
• EL-GABALAWY H, CANVIN J, VAN DER VIEREN M, HOFFMAN P, GALLATIN M, WILKINS J: Synovial distribution of αd/CD18, a novel leukointegrin. comparison with other integrins and their ligands. Arthritis Rheum. (1996) 39:1913-1921.
   PubMed Web of Science ®Google Scholar
• WATTS GM, BEURSKENS FJ, MARTIN-PADURA I et al.: Manifestations of inflammatory arthritis are critically dependent on LFA-1. J. Immunol. (2005) 174:3668-3675.
   Google Scholar
• ERICKSON AC, COUCHMAN JR: Still more complexity in mammalian basement membranes. J. Histochem. Cytochem. (2000) 48:1291-1306.
   Google Scholar
• HEINO J: The collagen receptor integrins have distinct ligand recognition and signaling functions. Matrix Biol. (2000) 19:319-323.
   PubMed Web of Science ®Google Scholar
• PROCKOP DJ, KIVIRIKKO KI. Collagens: molecular biology, diseases, and potentials for therapy. Ann. Rev. Biochem. (1995) 64:403-434.
   Web of Science ®Google Scholar
• KERN A, EBLE J, GOLBIK R, KUHN K: Interaction of type IV collagen with the isolated integrins α1β1 and α2β1. Eur. J. Biochem. (1993) 215:151-159.
   PubMedGoogle Scholar
• KERN A, BRIESEWITZ R, BANK I, MARCANTONIO EE: The role of the I domain in ligand binding of the human integrin α1β1. J. Biol. Chem. (1994) 269:22811-22816.
   PubMed Web of Science ®Google Scholar
• TULLA M, PENTIKAINEN OT, VIITASALO T et al.: Selective binding of collagen subtypes by integrin α1I, α2I, and α10I domains. J. Biol. Chem. (2001) 276:48206-48212.
   PubMed Web of Science ®Google Scholar
• SCHWARZBAUER J: Basement membranes: putting up the barriers. Curr. Biol. (1999) 9:R242-R244.
   Google Scholar
• HYNES RO: Integrins: versatility, modulation, and signalling in cell adhesion. Cell (1992) 69:11-25.
   PubMed Web of Science ®Google Scholar
• GOTWALS P, CHI-ROSSO G, LINDNER V et al.: The α1β1 integrin is expressed during neointima formation in rat arteries and mediates collagen matrix reorganization. J. Clin. Invest. (1996) 97:2469-2477.
   PubMed Web of Science ®Google Scholar
• RACINE-SAMSON L, ROCKEY DC, BISSELL DM: The role of α1β1 integrin in wound contraction. A quantitative analysis of liver myofibroblasts in vivo and in primary culture. J. Biol. Chem. (1997) 272:30911-30917.
   PubMed Web of Science ®Google Scholar
• MARCINKIEWICZ C, WEINREB PH, CALVETE JJ et al.: Obtustatin: a potent selective inhibitor of α1β1 integrin in vitro and angiogenesis in vivo. Cancer Res. (2003) 63:2020-2023.
   PubMed Web of Science ®Google Scholar
• POZZI A, WARY KK, GIANCOTTI FG, GARDNER HA: Integrin α1β1 mediates a unique collagen-dependent proliferation pathway in vivo. J. Cell Biol. (1998) 142:587-594.
   PubMed Web of Science ®Google Scholar
• RAO WH, HALES JM, CAMP RD: Potent costimulation of effector T lymphocytes by human collagen type I. J. Immunol. (2000) 165:4935-4940.
   Google Scholar
• LANGHOLZ O, ROCKEL D, MAUCH C et al.: Collagen and collagenase gene expression in three-dimensional collagen lattices are differentially regulated by α1β1 and α2β1 integrins. J. Cell Biol. (1995) 131:1903-1915.
   PubMed Web of Science ®Google Scholar
• GARDNER H, KREIDBERG J, KOTELIANSKY V, JAENISCH R: Deletion of integrin α1 by homologous recombination permits normal murine development but gives rise to a specific deficit in cell adhesion. Dev. Biol. (1996) 175:301-313.
   Google Scholar
• HEMLER ME, JACOBSON JG, BRENNER MB, MANN D, STROMINGER JL: VLA-1: a T cell surface antigen which defines a novel late stage of human T cell activation. Eur. J. Immunol. (1985) 15:502-508.
   Google Scholar
• RUBIO MA, SOTILLOS M, JOCHEMS G, ALVAREZ V, CORBI AL: Monocyte activation: rapid induction of α1/β1 (VLA-1) integrin expression by lipopolysaccharide and interferon-γ. Eur. J. Immunol. (1995) 25:2701-2705.
   Google Scholar
• DE FOUGEROLLES AR, SPRAGUE AG, NICKERSON-NUTTER CL et al.: Regulation of inflammation by collagen-binding integrins α1β1 and α2β1 in models of hypersensitivity and arthritis. J. Clin. Invest. (2000) 105:721-729.
   PubMed Web of Science ®Google Scholar
• HEMLER ME, GLASS D, COBLYN JS, JACOBSON JQ: Very late activation antigens on rheumatoid synovial fluid T lymphocytes. Association with stages of T cell activation. J. Clin. Invest. (1986) 78:696-702.
   PubMed Web of Science ®Google Scholar
• HANSSON GK, HOLM J, JONASSON L: Detection of activated T lymphocytes in the human atherosclerotic plaque. Am. J. Pathol. (1989) 135:169-175.
   PubMed Web of Science ®Google Scholar
• CORRIGAN CJ, HARTNELL A, KAY AB: T lymphocyte activation in acute severe asthma. Lancet (1988) 1:1129-1132.
   PubMed Web of Science ®Google Scholar
• ABRAHAM WM, AHMED A, SEREBRIAKOV I et al.: A monoclonal antibody to α1β1 blocks antigen-induced airway responses in sheep. Am. J. Respir. Crit. Care Med. (2004) 169:97-104.
   Google Scholar
• TANAKA T, OHTSUKA Y, YAGITA H, SHIRATORI Y, OMATA M, OKUMURA K: Involvement of α1 and α4 integrins in gut mucosal injury of graft-versus-host disease. Int. Immunol. (1995) 7:1183-1189.
   Google Scholar
• BANK I, HARDAN I, LOKSHIN E et al.: Parenteral administration of an activating monoclonal antibody to the α1β1 integrin in dogs. Immunobiology (2000) 202:239-253.
   PubMed Web of Science ®Google Scholar
• MEHARRA EJ, SCHON M, HASSETT D, PARKER C, HAVRAN W, GARDNER H: Reduced gut intraepithelial lymphocytes in VLA1 null mice. Cell Immunol. (2000) 201:1-5.
   PubMed Web of Science ®Google Scholar
• DICKESON SK, MATHIS NL, RAHMAN M, BERGELSON JM, SANTORO SA: Determinants of ligand binding specificity of the α1β1 and α2β1 integrins. J. Biol. Chem. (1999) 274:32182-32191.
   PubMed Web of Science ®Google Scholar
• KRIEGLSTEIN CF, CERWINKA WH, SPRAGUE AG et al.: Collagen-binding integrin α1β1 regulates intestinal inflammation in experimental colitis. J. Clin. Invest. (2002) 110:1773-1782.
   PubMed Web of Science ®Google Scholar
• FIORUCCI S, MENCARELLI A, PALAZZETTI B et al.: Importance of innate immunity and collagen binding integrin α1β1 in TNBS-induced colitis. Immunity (2002) 17:769-780.
   PubMed Web of Science ®Google Scholar
• BOEHNCKE WH, KELLNER I, KONTER U, STERRY W: Differential expression of adhesion molecules on infiltrating cells in inflammatory dermatoses. J. Am. Acad. Dermatol. (1992) 26:907-913.
   Google Scholar
• CONRAD C, BOYMAN O, DE FOUGEROLLES A, KOTELIANSKI V, GARDNER H, NESTLE FO: VLA-1 dependent intraepidermal T cell expansion is necessary for the development of psoriasis. Abstracts of Papers, 34th Annual European Society for Dermatological Research Meeting, Vienna, Austria (11 September 2004.) (Abstract 152).
   Google Scholar
• BOYMAN O, HEFTI HP, CONRAD C, NICKOLOFF BJ, SUTER M, NESTLE FO: Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-α. J. Exp. Med. (2004) 199:731-736.
   Google Scholar
• GOTWALS PJ, CHI-ROSSO G, RYAN ST et al.: Divalent cations stabilize the α1β1 integrin I domain. Biochemistry (1999) 38:8280-8288.
   PubMed Web of Science ®Google Scholar
• WELZENBACH K, HOMMEL U, WEITZ-SCHMIDT G: Small molecule inhibitors induce conformational changes in the I domain and the I-like domain of lymphocyte function-associated antigen-1. Molecular insights into integrin inhibition. J. Biol. Chem. (2002) 277:10590-10598.
   PubMed Web of Science ®Google Scholar
• KOLAKOWSKI GR, BJORNSON KL, JUDKINS A et al.: Identification of the potent small molecule inhibitors of VLA-1 integrin. Abstracts of Papers, 231st ACS National Meeting, Washington, DC, USA, (26 – 30 March 2006).
   Google Scholar
• HE L, PAPPAN LK, GRENACHE DG et al.: The contributions of the α2β1 integrin to vascular thrombosis in vivo. Blood (2003) 102:3652-3657.
   PubMed Web of Science ®Google Scholar
• GARDNER H, BROBERG A, POZZI A, LAATO M, HEINO J: Absence of integrin α1β1 in the mouse causes loss of feedback regulation of collagen synthesis in normal and wounded dermis. J. Cell Sci. (1999) 112(Part 3):263-272.
   Google Scholar
• CHEN X, MOECKEL G, MORROW JD et al.: Lack of integrin α1β1 leads to severe glomerulosclerosis after glomerular injury. Am. J. Pathol. (2004) 165:617-630.
   PubMed Web of Science ®Google Scholar
• SCHAPIRA K, LUTGENS E, DE FOUGEROLLES A et al.: Genetic deletion or antibody blockade of α1β1 integrin induces a stable plaque phenotype in ApoE-/- mice. Arterioscler Thromb. Vasc. Biol. (2005) 25:1917-1924.
   Google Scholar
• BEN HORIN S, BANK I: The role of very late antigen-1 in immune-mediated inflammation. Clin. Immunol. (2004) 113:119-129.
   Google Scholar
• RAY SJ, FRANKI SN, PIERCE RH et al.: The collagen binding α1β1 integrin VLA-1 regulates CD8 T cell-mediated immune protection against heterologous influenza infection. Immunity (2004) 20:167-179.
   PubMed Web of Science ®Google Scholar
• WOODSIDE DG: Dancing with multiple partners. Sci. STKE (2002) 2002:E14.
   Google Scholar
• LIU S, CALDERWOOD DA, GINSBERG MH: Integrin cytoplasmic domain-binding proteins. J. Cell Sci. (2000) 113:3563-3571.
   Google Scholar
• HORWITZ A, DUGGAN K, BUCK CA, BECKERLE MC, BURRIDGE K: Interaction of plasma membrane fibronectin receptor with talin-a transmembrane linkage. Nature (1986) 320:531-533.
   PubMed Web of Science ®Google Scholar
• OTEY CA, PAVALKO FM, BURRIDGE K: An interaction between α actinin and the β1 integrin subunit in vitro. J. Cell Biol. (1990) 111:721-729.
   PubMed Web of Science ®Google Scholar
• SCHALLER MD, OTEY CA, HILDEBRAND JD, PARSONS JT: Focal adhesion kinase and paxillin bind to peptides mimicking β integrin cytoplasmic domains. J. Cell Biol. (1995) 130:1181-1187.
   PubMed Web of Science ®Google Scholar
• WOODSIDE DG, OBERGFELL A, LENG L et al.: Activation of Syk protein tyrosine kinase through interaction with integrin β cytoplasmic domains. Curr. Biol. (2001) 11:1799-1804.
   Web of Science ®Google Scholar
• ARIAS-SALGADO EG, LIZANO S, SARKAR S, BRUGGE JS, GINSBERG MH, SHATTIL SJ: Src kinase activation by direct interaction with the integrin β cytoplasmic domain. Proc. Natl. Acad. Sci. USA (2003) 100:13298-13302.
   PubMed Web of Science ®Google Scholar
• VIJAYAN KV, LIU Y, LI TT, BRAY PF: Protein phosphatase 1 associates with the integrin αIIb subunit and regulates signaling. J. Biol. Chem. (2004) 279:33039-33042.
   PubMed Web of Science ®Google Scholar
• CALDERWOOD DA, FUJIOKA Y, DE PEREDA JM et al.: Integrin β cytoplasmic domain interactions with phosphotyrosine-binding domains: a structural prototype for diversity in integrin signaling. Proc. Natl. Acad. Sci. USA (2003) 100:2272-2277.
   PubMed Web of Science ®Google Scholar
• LIU S, THOMAS SM, WOODSIDE DG et al.: Binding of paxillin to α4 integrins modifies integrin-dependent biological responses. Nature (1999) 402:676-681.
   PubMed Web of Science ®Google Scholar
• BIANCHI E, DENTI S, GRANATA A et al.: Integrin LFA-1 interacts with the transcriptional co-activator JAB1 to modulate AP-1 activity. Nature (2000) 404:617-621.
   PubMed Web of Science ®Google Scholar
• GOLDFINGER LE, HAN J, KIOSSES WB, HOWE AK, GINSBERG MH: Spatial restriction of α4 integrin phosphorylation regulates lamellipodial stability and α4β1-dependent cell migration. J. Cell Biol. (2003) 162:731-741.
   PubMed Web of Science ®Google Scholar
• HAN J, ROSE DM, WOODSIDE DG, GOLDFINGER LE, GINSBERG MH: Integrin α4β1-dependent T cell migration requires both phosphorylation and dephosphorylation of the α4 cytoplasmic domain to regulate the reversible binding of paxillin. J. Biol. Chem. (2003) 278:34845-34853.
   PubMed Web of Science ®Google Scholar
• NISHIYA N, KIOSSES WB, HAN J, GINSBERG MH: An α4 integrin–paxillin–Arf–GAP complex restricts Rac activation to the leading edge of migrating cells. Nat. Cell Biol. (2005) 7:343-352.
   Google Scholar
• FERAL CC, ROSE DM, HAN J et al.: Blocking the α4 integrin–paxillin interaction selectively impairs mononuclear leukocyte recruitment to an inflammatory site. J. Clin. Invest. (2006) 116:715-723.
   PubMed Web of Science ®Google Scholar
• AMBROISE Y, YASPAN B, GINSBERG MH, BOGER DL: Inhibitors of cell migration that inhibit intracellular paxillin/α4 binding: a well-documented use of positional scanning libraries. Chem. Biol. (2002) 9:1219-1226.
   Google Scholar
• BOUGIE DW, WILKER PR, WUITSCHICK ED et al.: Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood (2002) 100:2071-2076.
   PubMed Web of Science ®Google Scholar
• BEDNAR B, COOK JJ, HOLAHAN MA et al.: Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa. Blood (1999) 94:587-599.
   PubMed Web of Science ®Google Scholar
• MOCHLY-ROSEN D, GORDO AS: Anchoring proteins for protein kinase C: a means for isozyme selectivity. FASEB J. (2000) 12:35-42.
   Web of Science ®Google Scholar
• MOCSAI A, ZHOU M, MENG F, TYBULEWICZ VL, LOWELL CA: Syk is required for integrin signaling in neutrophils. Immunity (2002) 16:547-558.
   PubMed Web of Science ®Google Scholar
• KEANE J, GERSHON S, WISE RP et al.: Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med. (2001) 345:1098-1104.
   PubMed Web of Science ®Google Scholar
• PAGNOUX C, HAYEM G, ROUX F et al.: JC virus leukoencephalopathy complicating Wegener’s granulomatosis. Joint Bone Spine (2003) 70:376-379.
   PubMed Web of Science ®Google Scholar
• SCHNEIDER F: [Progressive multifocal leukoencephalopathy as a cause of neurologic symptoms in Sharp syndrome]. Z. Rheumatol. (1991) 50:222-224.
   PubMed Web of Science ®Google Scholar